Journey Medical (DERM) Total Non-Current Liabilities (2020 - 2024)
Journey Medical's (DERM) quarterly Total Non-Current Liabilities came in at $60.2 million in Q4 2024, up 6.5% YoY from $56.5 million in Q1 2024, and up 6.5% on a QoQ basis from $56.5 million in Q4 2023.
Journey Medical (DERM) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Journey Medical (DERM) has 5 years of Total Non-Current Liabilities data on file, last reported at $60.2 million in Q4 2024.
- Quarterly Total Non-Current Liabilities rose 6.5% year-over-year to $60.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $60.2 million (up 6.5% YoY) and the FY2024 annual result came in at $60.2 million, up 6.5% from the prior year.
- Total Non-Current Liabilities climbed to $60.2 million in Q4 2024, from $56.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $96.4 million in Q3 2021 to a low of $33.5 million in Q4 2020.
- A 5-year average of $70.1 million and a median of $74.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 68.11% — and 2023, when it sank 34.88%.
- Tracing DERM's Total Non-Current Liabilities over 5 years: stood at $33.5 million in 2020, then soared by 54.18% to $51.6 million in 2021, then soared by 68.11% to $86.8 million in 2022, then sank by 34.88% to $56.5 million in 2023, then rose by 6.5% to $60.2 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $60.2 million (Q4 2024), $56.5 million (Q4 2023), and $68.3 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Journey Medical | 205.52 Mn | 179.87 Mn | 12.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 60.17 Mn |
| Dec 31, 2023 | 56.50 Mn |
| Jun 30, 2023 | 68.25 Mn |
| Mar 31, 2023 | 86.91 Mn |
| Dec 31, 2022 | 86.77 Mn |
| Sep 30, 2022 | 80.59 Mn |
| Jun 30, 2022 | 74.89 Mn |
| Mar 31, 2022 | 75.75 Mn |
| Dec 31, 2021 | 51.61 Mn |
| Sep 30, 2021 | 96.40 Mn |
| Dec 31, 2020 | 33.48 Mn |